Comparing the effect of edible olibanum, and curcumin on blood and inflamatory factors in rheumatoid arthritis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017011614925N2

Enrollment

Registered

2017-11-07

Start date

2017-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Seropositive rheumatoid arthritis

Interventions

Intervention 1: Second intervention group: Three capsules of 500 mg olibanum, Daily, for 3 months. Intervention 2: First intervention group 1: Three capsules of Nano curcumin 40 mg, daily for 3 months

Treatment - Drugs

Placebo

Second intervention group: Three capsules of 500 mg olibanum, Daily, for 3 months

First intervention group 1: Three capsules of Nano curcumin 40 mg, daily for 3 months

Control group: Three 500 mg capsol of wheat flour daily, for 3 months

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willing to participate in study; Clinical diagnosis of rheumatoid arthritis (meeting the American college of rheumatology 1987 criteria); No smoking or addiction; No drug type and dose fluctuation since 1 month prior to the study and during intervention period ; Not having severe cardiovascular; Hepatic; Kidney; Gastrointestinal; Thyroid; Parathyroid diseases; Diabetes and inflammation; Not using medications except for AR conventional drugs; No pregnancy or lactation Exclusion criteria: Developing illnesses which need particular cures or interfere with intervention such as increasing the disease activity or trauma; alcoholic; sensitivity to olibanum and turmeric

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hs- CRP. Timepoint: Befor intervention, End of the intervention. Method of measurement: ELISA.;Blood lipid. Timepoint: Befor intervention, End of the intervention. Method of measurement: Laboratory.;Fasting insulin. Timepoint: Befor intervention, End of the intervention. Method of measurement: HOMA-IR.	—

Secondary

Measure	Time frame
Serum levels of Total Antioxidant Capacity. Timepoint: Befor intervention, End of the intervention. Method of measurement: Laboratory ELISA.;Rheumatoid factor. Timepoint: Befor intervention, End of the intervention. Method of measurement: Laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Javadi

Qazvin University of Medical Sciences

mjavadi@qums.ac.ir+98 28 3333 6005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026